Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Hypersensitivity Reaction

  Free Subscription


Articles published in Eur J Dermatol

Retrieve available abstracts of 53 articles:
HTML format



Single Articles


    July 2022
  1. PIOTIN A, Hacard F, Crumbach L, Nicolas JF, et al
    Anaphylaxis to chlorhexidine after taking oral medication
    Eur J Dermatol. 2022;32:551-553.
    PubMed    


  2. BRAUN C, Patra V, Lina G, Nicolas JF, et al
    The role of skin dysbiosis in atopic dermatitis
    Eur J Dermatol. 2022;32:439-444.
    PubMed     Abstract available


  3. WOLLENBERG A, Lio P, Kleyn E, Bissonnette R, et al
    Improvement of head and neck symptoms in patients with atopic dermatitis treated with baricitinib based on five Phase III clinical trials
    Eur J Dermatol. 2022;32:522-529.
    PubMed     Abstract available


  4. SERRANO ORDONEZ A, Lopez Riquelme I, Perea Polak A
    sQuiz your knowledge! Persistent unilateral facial and lip swelling
    Eur J Dermatol. 2022;32:562-563.
    PubMed    


  5. KITAYAMA S, Makino T, Kataoka K, Mori S, et al
    Valacyclovir-induced drug reaction with eosinophilia and systemic symptoms
    Eur J Dermatol. 2022;32:538-539.
    PubMed    


  6. MARTINEZ-SAGUER I, Dominas N, Straben U, Greve J, et al
    Patients with hereditary angioedema and their treatment patterns in Germany: a Delphi consensus study
    Eur J Dermatol. 2022;32:487-494.
    PubMed     Abstract available


  7. PANKAKOSKI A, Kluger N, Sintonen H, Panelius J, et al
    Clinical manifestations and comorbidities of pemphigus: a retrospective case-control study in southern Finland
    Eur J Dermatol. 2022;32:480-486.
    PubMed     Abstract available


    May 2022
  8. LEFEVRE MA
    "Prick or treat": a case of systemic reaction during intradermal tests with beta-lactams
    Eur J Dermatol. 2022;32:426-428.
    PubMed    


  9. FUJISHIMA C, Munemoto S, Hioki C, Sasaki H, et al
    Successful dupilumab therapy for atopic dermatitis in a patient with X-linked agammaglobulinaemia
    Eur J Dermatol. 2022;32:416-417.
    PubMed    


  10. NAKAGAWA M, Hanada M, Amano H
    Allergic contact stomatitis caused by (meth)acrylates following sensitization by artificial nails, 20 years previously
    Eur J Dermatol. 2022;32:413-415.
    PubMed    


  11. ROLO DE MATOS P, Nogueira A, Gomes N, Costa C, et al
    Rare presentation of Wells syndrome mimicking angioedema: a case report
    Eur J Dermatol. 2022;32:411-413.
    PubMed    


  12. ULDAHL A, Sterner T, Bruze M, Dahlin J, et al
    Atopy patch testing and associations with atopic conditions and specific IgE tests: a population-based study in adolescents
    Eur J Dermatol. 2022;32:384-393.
    PubMed     Abstract available


  13. GUILLON C, Meziani M, Abdelli S, Sigaudo Roussel D, et al
    The aryl hydrocarbon receptor pathway plays a central role in the cutaneous response to pollutants
    Eur J Dermatol. 2022;32:305-311.
    PubMed     Abstract available


    April 2022
  14. SCHUSTER B, Ziehfreund S, Schielein MC, Tizek L, et al
    Adding happiness to complement the Dermatology Quality of Life Index in psoriasis and atopic dermatitis healthcare: a cross-sectional study
    Eur J Dermatol. 2022;32:220-226.
    PubMed     Abstract available


  15. MASUDA K, Delozier AM, Kolodsick J, Buchanan A, et al
    Improvements in itch and sleep following treatment with baricitinib in combination with topical corticosteroids are associated with better quality of life and productivity in adult patients with moderate-to-severe atopic dermatitis: a post hoc analysi
    Eur J Dermatol. 2022;32:237-243.
    PubMed     Abstract available


  16. STEFANIAK AA, Knecht K, Matusiak L
    sQuiz your knowledge! Non-pruritic chronic urticaria and recurrent episodes of fever
    Eur J Dermatol. 2022;32:300-301.
    PubMed    


    February 2022
  17. VAN HALEWIJN KF, Lahnstein T, Bohnen AM, Van Den Berg PJ, et al
    Recommendations for emollients, bathing and topical corticosteroids for the treatment of atopic dermatitis: a systematic review of guidelines.
    Eur J Dermatol. 2022 Feb 21. pii: ejd.2022.4197. doi: 10.1684/ejd.2022.4197.
    PubMed     Abstract available


  18. NADA HR, Rashed LA, Shehada J, Mostafa PIN, et al
    Phosphodiesterase 4 (PDE4) gene expression in atopic dermatitis patients, before and after treatment with topical mometasone cream.
    Eur J Dermatol. 2022 Feb 15. pii: ejd.2022.4194. doi: 10.1684/ejd.2022.4194.
    PubMed     Abstract available


  19. ESCURE G, Nudel M, Terriou L, Farhat MM, et al
    Tolerance of bradykinin-releasing drugs in patients with acquired C1 inhibitor deficiency: a case series and review of the literature.
    Eur J Dermatol. 2022;32:49-55.
    PubMed    


    January 2022
  20. LEFEVRE MA, Mosnier A
    A case of paracetamol-induced nonpigmented fixed drug eruption confirmed by a lymphocyte transformation test.
    Eur J Dermatol. 2022;32:154-156.
    PubMed    


  21. SHEN X, Zhang W, Li X, Lu H, et al
    Association between serum IgG and Henoch-Schonlein purpura with renal involvement in children: a cross-sectional study.
    Eur J Dermatol. 2022;32:132-134.
    PubMed    


    December 2021
  22. SALAVA A, Perala M, Juppo M, Pelkonen AS, et al
    Effective treatment of atopic dermatitis in small children significantly improves the quality of life of patients and their families.
    Eur J Dermatol. 2021 Dec 21. pii: ejd.2021.4169. doi: 10.1684/ejd.2021.4169.
    PubMed     Abstract available


  23. EGEBERG A, Anderson P, Piercy J, Massey L, et al
    Symptom burden of patients with moderate-to-severe atopic dermatitis.
    Eur J Dermatol. 2021 Dec 21. pii: ejd.2021.4166. doi: 10.1684/ejd.2021.4166.
    PubMed     Abstract available


  24. LORET L, Ninclaus V, Dendooven A, Lapeere H, et al
    Canalicular stenosis associated with dupilumab treatment for atopic dermatitis.
    Eur J Dermatol. 2021 Dec 17. pii: ejd.2021.4180. doi: 10.1684/ejd.2021.4180.
    PubMed    


  25. CHESTER J, Kaleci S, Liberati S, Alicandro T, et al
    Atopic dermatitis associated with autoimmune, cardiovascular and mental health comorbidities: a systematic review and meta-analysis.
    Eur J Dermatol. 2021 Dec 15. pii: ejd.2021.4168. doi: 10.1684/ejd.2021.4168.
    PubMed     Abstract available


  26. LEFEVRE MA, Mohme S, Alband N, Nogueira M, et al
    Journal club: New small molecules for atopic dermatitis management.
    Eur J Dermatol. 2021;31:849-852.
    PubMed    


  27. TRAIDL S, Heratizadeh A, Werfel T, Dressler C, et al
    Online survey to identify current challenges in atopic dermatitis management and guideline implementation in German-speaking countries.
    Eur J Dermatol. 2021;31:806-812.
    PubMed     Abstract available


  28. ROVATI C, Rossi M, Gelmetti A, Tomasi C, et al
    Impact of the COVID-19 pandemic and lockdown on the clinical response to dupilumab treatment and the psychological status of non-infected atopic patients.
    Eur J Dermatol. 2021;31:736-740.
    PubMed     Abstract available


  29. RAVAL NS, Snowden CK, De Monnin KS, Yokoyama CC, et al
    Scarring alopecia developing after mogamulizumab-associated rash.
    Eur J Dermatol. 2021;31:841-843.
    PubMed    


  30. SUKAKUL T, Svedman C, Dahlin J, Bergendorff O, et al
    Simultaneous positive patch test reactions to neomycin and low-molecular-weight heparins: possible cross-reaction?
    Eur J Dermatol. 2021;31:741-743.
    PubMed     Abstract available


    October 2021
  31. KURIHARA K, Fujiyama T, Tokura Y, Honda T, et al
    Two cases of psoriasiform dermatitis arising during dupilumab therapy and successfully treated with delgocitinib ointment.
    Eur J Dermatol. 2021 Oct 26. pii: ejd.2021.4140. doi: 10.1684/ejd.2021.4140.
    PubMed    


  32. KHELLAF L, Cosserat J, Calas A, Brasme H, et al
    Unusual neurological and cardiac complications of drug reaction with eosinophilia and systemic symptoms syndrome: a case report.
    Eur J Dermatol. 2021;31:652-654.
    PubMed    


  33. FANG YH, Wei KC, Yu MS
    Improvement of erythema elevatum diutinum refractory to dapsone following treatment for underlying multiple myeloma.
    Eur J Dermatol. 2021;31:655-657.
    PubMed    


    August 2021
  34. INGEN-HOUSZ-ORO S, Staumont-Salle D, Palladini A, Ferries L, et al
    Immunosuppressants as steroid-sparing agents for chronic DRESS: four cases.
    Eur J Dermatol. 2021;31:576-577.
    PubMed    


    June 2021
  35. LEFEVRE MA, Nosbaum A
    Dermpath and Clinic: How to manage adverse reactions to biological agents.
    Eur J Dermatol. 2021;31:426-427.
    PubMed    


  36. CUI Y, Shi J, Wang C, Vinturache A, et al
    Therapeutic plasma exchange combined with continuous venovenous hemofiltration in a series of pediatric patients with toxic epidermal necrolysis.
    Eur J Dermatol. 2021;31:413-415.
    PubMed    


  37. WATABE D, Amano H
    TNF-alpha inhibitor-induced paradoxical psoriasis and erythema nodosum in a patient with ankylosing spondylitis.
    Eur J Dermatol. 2021;31:412-413.
    PubMed    


  38. PERRON E, Viarnaud A, Marciano L, Karkouche R, et al
    Clinical and histological features of fixed drug eruption: a single-centre series of 73 cases with comparison between bullous and non-bullous forms.
    Eur J Dermatol. 2021;31:372-380.
    PubMed     Abstract available


  39. SUGINO H, Nakamura M
    Mild hypertrichosis in both upper arms around dupilumab injection sites.
    Eur J Dermatol. 2021;31:420-421.
    PubMed    


    April 2021
  40. MORIMOTO H, Fukuchi K, Ogura Y, Ohtsuka M, et al
    Development of lichen planus following benralizumab treatment.
    Eur J Dermatol. 2021 Apr 2. pii: ejd.2021.3995. doi: 10.1684/ejd.2021.3995.
    PubMed    


  41. GIORDANO-LABADIE F, Becherel PA, Pralong P, Outtas O, et al
    Improvement of patient outcomes following therapeutic optimization of chronic urticaria: two-year data from France as part of the international real-life AWARE study.
    Eur J Dermatol. 2021;31:217-224.
    PubMed     Abstract available


    March 2021
  42. KIRSTEN N, Mohr N, Maul JT, Augustin M, et al
    Incidence of atopic conditions in people with psoriasis: a population-based analysis.
    Eur J Dermatol. 2021 Mar 1. pii: ejd.2021.3963. doi: 10.1684/ejd.2021.3963.
    PubMed     Abstract available


    February 2021
  43. BELBEZIER A, Boccon-Gibod I, Bouillet L
    Efficacy of omalizumab for extracutaneous symptoms of chronic spontaneous urticaria.
    Eur J Dermatol. 2021;31:86-87.
    PubMed    


  44. KOMATSU-FUJII T, Ogawa M, Nonoyama S, Fukumoto T, et al
    Recurrence of nivolumab-induced Stevens-Johnson syndrome due to tegafur/gimeracil/oteracil (TS-1(R)) after nivolumab discontinuation.
    Eur J Dermatol. 2021;31:98-99.
    PubMed    


  45. KUMANO Y, Nagai A, Sugiura K
    Erythro-papular type drug eruption caused by fosravuconazole L-lysine ethanolate.
    Eur J Dermatol. 2021;31:90-91.
    PubMed    


  46. UGAJIN T, Namiki T, Yokozeki H
    A case of prurigo caused by hair dye containing p-phenylenediamine: histopathological findings.
    Eur J Dermatol. 2021;31:103-104.
    PubMed    


  47. MAKIHARA-INUKAI M, Takeichi T, Ogawa-Momohara M, Muro Y, et al
    Morphea in a Crohn's disease patient undergoing ustekinumab treatment.
    Eur J Dermatol. 2021;31:96-97.
    PubMed    


  48. FAUCON C, Bernigaud C, Sbidian E, Hue S, et al
    Essential oils as potential triggers for bullous pemphigoid? A report of two patients.
    Eur J Dermatol. 2021;31:92-93.
    PubMed    


  49. HAYAMA K, Fujita H, Asai-Sato M, Kawana K, et al
    Successful treatment of intractable chronic spontaneous urticaria with omalizumab in a patient with ovarian cancer.
    Eur J Dermatol. 2021;31:100-101.
    PubMed    


    January 2021
  50. NAGASAWA Y, Iinuma S, Fujii M, Kanno K, et al
    Dasatinib-induced panniculitis in a patient with chronic myeloid leukaemia.
    Eur J Dermatol. 2021 Jan 25. pii: ejd.2020.3946. doi: 10.1684/ejd.2020.3946.
    PubMed    


  51. COSTEDOAT I, Vergara R, Dousset L, Gerard E, et al
    Drug-induced bullous lichenoid eruption: a side effect of nivolumab triggered by the TLR agonist imiquimod.
    Eur J Dermatol. 2021 Jan 15. pii: ejd.2020.3951. doi: 10.1684/ejd.2020.3951.
    PubMed    


    December 2020
  52. DANSET M, Hacard F, Jaulent C, Nosbaum A, et al
    Brodalumab-associated generalized eczematous eruption in a difficult-to-treat psoriasis patient: management without brodalumab withdrawal.
    Eur J Dermatol. 2020 Dec 18. pii: ejd.2020.3910. doi: 10.1684/ejd.2020.3910.
    PubMed    


    November 2020
  53. KIMURA R, Sugita K, Yamamoto O
    Successful switching to brodalumab in a patient with severe psoriasis developing ixekizumab-induced eczema.
    Eur J Dermatol. 2020 Nov 24. pii: ejd.2020.3904. doi: 10.1684/ejd.2020.3904.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Hypersensitivity Reaction is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: